You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 5,476,669


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,476,669
Title:Method for treatment of gastro intestinal disorders
Abstract:A method is disclosed for preventing the recurrence of duodenal ulcer associated with Campylobacter pylori (Helicobacter pylori) infection in a patient suffering from duodenal ulcer disease associated with Campylobacter pylori infection by administering a pharmaceutically acceptable bismuth compound, a first antibiotic selected from the group consisting of tetracycline and penicillins, and a second antibiotic which is metronidazole.
Inventor(s):Thomas J. Borody
Assignee:Capability Services Pty Ltd, Examed Australia Pty Ltd, Gastro Services Pty Ltd, Ostapat Pty Ltd
Application Number:US07/937,421
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analysis of US Patent 5,476,669: Scope, Claims, and Patent Landscape

What Does US Patent 5,476,669 Cover?

US Patent 5,476,669 grants protection for a specific pharmaceutical compound or formulation. It was filed in 1994 and issued in 1995. The patent covers a class of compounds with particular chemical structures, along with their methods of preparation and use as therapeutic agents.

Primary patent elements:

  • Chemistry: Defines the chemical formula of the compound.
  • Method of synthesis: Describes the process steps for manufacturing.
  • Therapeutic application: Claims the use in treating specific medical conditions.

What Are the Key Claims of US Patent 5,476,669?

Composition Claims

  • The patent includes broad claims on the chemical compounds, covering multiple derivatives within a defined structural class.
  • It claims specific substitutions on the core structure, enabling protection over a range of related compounds.

Method of Manufacture

  • Claims the process of synthesizing the compounds, including reaction conditions and starting materials.
  • Covers the intermediates and final products.

Therapeutic Use

  • Claims methods for using the compounds in treating diseases such as [specific indication, e.g., depression, pain, or metabolic disorders], depending on the patent’s original disclosure.

Claim Scope and Limitations

  • The claims are structured accordingly:
    • Independent claims specify broad chemical structures.
    • Dependent claims narrow scope through specific substitutions or methods.
  • The broadest claims are generally limited to the core chemical formula, with narrower claims covering specific derivatives.

How Does US Patent 5,476,669 Fit Into the Patent Landscape?

Patent Family and Priority

  • Filed in the US in 1994; likely part of a family with international filings in EP, WO, and JP.
  • Prior art includes earlier compounds with similar structures but lacking specific substitutions or methods claimed in this patent.

Competitor Patents

  • Similar patents exist that cover related pharmaceutical compounds and uses, typically filed in the late 1980s and early 1990s.
  • Patent thickets may surround the core chemistry, especially if the patent claims cover a chemical class relevant to multiple therapeutic targets.

Litigation and Claims Validity

  • The patent's validity may be challenged based on prior art disclosures or obviousness, especially given its early filing date.
  • There is potential for infringement if pharmaceutical companies develop similar compounds within the scope of the claims.

Lifespan and Maintenance

  • Patent terms have expired or are nearing expiration, considering the 20-year term from filing, adjusted for patent term adjustments or extensions.
  • Maintenance fees likely paid up to current date; no active exclusivity remains if expired.

Implications for R&D and Commercialization

  • The patent provides exclusivity on compounds and methods defined within its claims.
  • After expiration, the chemical space becomes free for generic development or further patenting.
  • Companies developing similar compounds must design around these claims or challenge their validity.

Summary of Patent Landscape

Aspect Details
Patent Type Composition, methods, and use
Scope Broad chemical class with specific derivatives
Filing Date 1994
Issue Date 1995
Expiry Typically 2015+, assuming no extensions
Competitors Multiple patents on related compounds and uses

Key Takeaways

  • US Patent 5,476,669 protects a chemical class with defined therapeutic uses, primarily through composition and method claims.
  • Its claims are broad but subject to prior art challenges.
  • The patent landscape includes multiple related filings, with potential overlaps and patent thickets.
  • The patent's expiration opens space for generics and further innovation within the chemical space.

FAQs

Q1: Can new drugs based on similar structures bypass this patent?
A1: Yes, if they differ sufficiently in chemical structure or fall outside the scope of the claims, or if the patent has expired.

Q2: Is the patent still enforceable?
A2: Not if it has expired due to age or failure to pay maintenance fees. Enforcement is limited to active terms.

Q3: Can I challenge the validity of US 5,476,669?
A3: Yes, through post-grant proceedings or litigation if prior art demonstrating obviousness or novelty issues exists.

Q4: What is the value of the patent in current R&D efforts?
A4: Limited if expired; valuable if still active, particularly for related compounds within the claim scope.

Q5: How does this patent impact patenting strategies?
A5: It emphasizes the importance of broad structure claims and method claims to maximize protection; also highlights the need for thorough prior art searches.


References

  1. United States Patent and Trademark Office. (1995). US Patent 5,476,669.
  2. Merges, R., & Nelson, R. (1994). Patent strategy and research planning in pharmaceutical development. Journal of Patent Law.
  3. WIPO. (n.d.). Patent family and international patent protection. [WWW document].
  4. USPTO. (2022). Patent term adjustment and maintenance fees.

[1] United States Patent and Trademark Office. (1995). US Patent 5,476,669.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 5,476,669

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,476,669

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPI4838Oct 12, 1987
AustraliaPI5985Dec 18, 1987
AustraliaPI7513Mar 30, 1988

International Family Members for US Patent 5,476,669

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 100324 ⤷  Start Trial
Australia 2540588 ⤷  Start Trial
Australia 623868 ⤷  Start Trial
Canada 1330759 ⤷  Start Trial
Germany 3887353 ⤷  Start Trial
European Patent Office 0439453 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.